NIMG-93. DISCRIMINATION OF CLINICALLY IMPACTFUL TREATMENT RESPONSE IN RECURRENT GLIOBLASTOMA PATIENTS RECEIVING BEVACIZUMAB TREATMENT

INTRODUCTION: Clinicians have few effective tools for assessing treatment response in glioblastoma that are predictive of patient outcomes. In previous work, a personalized response metric based on a proliferation-invasion tumor mathematical model, Days Gained, was prognostic for progression-free an...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Neuro Oncol
Главные авторы: Singleton, Kyle W, Johnston, Sandra K, Hawkins-Daarud, Andrea, Rickertsen, Cassandra R, De Leon, Gustavo, Kunkel, Lauren, Whitmire, Scott A, Clark-Swanson, Kamala, Bendok, Bernard, Mrugala, Maciej, Porter, Alyx, Swanson, Kristin R
Формат: Artigo
Язык:Inglês
Опубликовано: Oxford University Press 2017
Предметы:
Abstracts
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5692666/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.662
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы